Epidermal growth factor receptor in colorectal carcinoma: Correlation with clinico-pathological prognostic factors

Colorectal Disease

Volumn 10, Issue 2, 2008, Pages 170-178

  Abd El All, Howay S ^a,b   Mishriky, A M ^a   Mohamed, F A ^b  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b Maadi Armed Forces Hospital   (Egypt)

Author keywords

Colorectal carcinoma; EGFR scoring; IHC standardization; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER INVASION; COLORECTAL CARCINOMA; CORRELATIONAL STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; STANDARDIZATION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAINING AND LABELING;

EID: 38349046782     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2007.01306.x     Document Type: Article

References (41)

1. National Cancer Registry. (2000) Highlight. The National Cancer Registry Newsletter. Ministry of Health and Population, Egypt.
2. Compton CC, Fielding PL, Burgart LJ et.al. Prognostic Factors in Colorectal Cancer: College of American Pathologists Consensus Statement. Arch Pathol Lab Med 1999; 124:979-94.
3. Wang Y, Minoshima S, Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. Jpn J Hum Genet 1993; 38:399-406.
4. Coffey RJ Jr, Goustin AS, Soderquist AM et.al. Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res 1987; 47:4590-94.
5. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265:7709-12.
6. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47:87-98.
7. De Jong KP, Stellema R, Karrenbeld A et.al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998; 28:971-79.
8. Hemming AW, Davis NL, Kluftinger A et.al. Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51:147-52.
9. Shirai H, Ueno E, Osaki M et.al. Expression of growth factors and their receptors in human early colorectal carcinomas: Immunohistochemical study. Anticancer Res 1995; 15:2889-94.
10. Spano JP, Lagorce C, Atlan D et.al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005; 16:102-08.
11. Galizia G, Lieto E, Ferraraccio F et.al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13:823-35.
12. Scartozzi M, Bearzi I, Berardi R et.al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22:4772-78.
13. Resnick MB, Routhier J, Konkin T et.al. Epidermal growth factor receptor, c-MET, ß-Catenin, and p53 expression as prognostic indicators in stage ii colon cancer. A Tissue Microarray Study. Clin Cancer Res 2004; 10:3069-75.
14. Bralet MP, Paule B, Adam R et.al. Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J Clin Oncol 2005; 23:5844.
15. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30:255-68.
16. Cunningham D, Humblet Y, Siena S et.al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
17. Saltz LB, Meropol NJ, Loehrer PJ et.al. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-04.
18. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. The Oncologist 2005; 10:701-09.
19. Hamilton SR, Aaltonen LA. (2000) WHO Classification of Tumours. Pathology and Genetics of Tumours of Digestive System. IARC Press, Lyon.
20. Greene FL, Page DL, Fleming ID et.al (2002 6th edition). AJCC: Cancer Staging Handbook: From the AJCC Cancer Staging Manual. Springer Verlag, New York, pp. 127-9.
21. Atkins D, Reiffen K-A, Tegtmeier CL et.al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histo Cytohem 2004; 52:893-901.
22. Allred DC, Harvey JM, Berardo MD et.al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998: 11:155-68.
23. Saltz L. In reply. J Clin Oncol 2005; 23:923-24.
24. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001; 92:1331-46.
25. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006; 24:2158-63.
26. Mattoon D, Klein P, Lemmon MA et.al. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. PNAS 2004; 101:923-28.
27. Shuch B, Mikhail M, Satagopan J et.al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 2004; 22:4725-29.
28. Soliman AS, Bondy ML, El-Badawy SA et.al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001; 85:1037-46.
29. Steele RJ, Kelly P, Ellul B et.al. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77:1352-54.
30. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virch Arch A Pathol Anat Histopathol 1990; 416:343-49.
31. Karameris A, Kanavaros P, Aninos D et.al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract 1993; 189:133-37.
32. McKay JA, Murray LJ, Curran S et.al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38:2258-64.
33. Khalifa MA, Rowsell CH, Gladdy RA et.al. Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. Am J Clin Pathol 2006; 125:229-33.
34. Santiskulvong C, Sinnett-Smith J, Rozengurt E. EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. Am J Physiol Cell Physiol 2001; 281:C886-98.
35. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006; 94:184-88.
36. Brunton VG, Ozanne BW, Paraskeva C et.al. A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 1997; 14:283-93.
37. Hauck CR, Sieg DJ, Hsia DA et.al. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 2001; 61:7079-90.
38. Wilson AG, Gibson PR. Role of epidermal growth factor receptor in basal and stimulated colonic epithelial cell migration in vitro. Exp Cell Res 1999; 250:187-96.
39. Pai R, Nakamura T, Moon WS et.al. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003; 17:1640-47.
40. Shao J, Evers BM, Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 2004; 279:14287-93.
41. Parikh AA, Fan F, Liu WB et.al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004; 164:2139-51.